Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome with the main characteristic of diffuse liver cells with fatty changes. The clinical evolution of NAFLD includes simple non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), liver fibrosis and cirrhosis, and even hepatocellular carcinoma. METHODS AND FINDINGS: We conducted this review to identify the effectiveness of omega-3 polyunsaturated fatty acids (ω-3 PUFA) in NAFLD. We searched PubMed, Cochrane Library and Embase. All randomized controlled trials (RCTs) of ω-3 PUFA treatment for NAFLD were considered. Two reviewers assessed the quality of each study and collected data independently. Disagreements were resolved by discussion among the reviewers and any of the other authors of the paper. We performed a meta-analysis and reported summary estimates of outcomes as inverse variance (IV), fixed or random, with 95% confidence intervals (CIs). We included seven RCTs involving 442 patients (227 for the experimental group and 215 for the control group). All the patients were divided into two groups: one treated with ω-3 PUFA and the other was the control group (generally placebo). The demographics of the ω-3 PUFA and control groups were comparable. Beneficial changes in alanine aminotransferase (ALT) (IV 95% CI: -7.61 [-12.83 to -2.39], p = 0.004), total cholesterol (TC) (IV 95% CI: -13.41 [-21.44 to -5.38], p = 0.001), triglyceride (TG) (IV 95% CI: -43.96 [-51.21 to -36.71], p<0.00001) and high-density lipoprotein cholesterol (HDL-C) (IV 95% CI: 6.97 [2.05 to 11.90], p = 0.006) favored ω-3 PUFA treatment. Omega-3 PUFA tended towards a beneficial effect on aspartate aminotransferase (AST) (IV 95% CI: -6.89 [-17.71 to 3.92], p = 0.21), γ-glutamyl transferase (GGT) (IV 95% CI: -8.28 [-18.38 to 1.83], p = 0.11) and low-density lipoprotein cholesterol (LDL-C) (IV 95% CI: -7.13 [-14.26 to 0.0], p = 0.05). CONCLUSIONS: Supplementation with ω-3 PUFA is a practical and effective treatment for NAFLD to decrease ALT, TC and increase HDL-C, especially to decrease TG. Omega-3 PUFA also has a tendency toward a beneficial effect on AST, GGT and LDL-C. More high-quality, large RCTs are needed to validate our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
ARAYA, J., RODRIGO, R., VIDELA, L. A., THIELEMANN, L., ORELLANA, M., PETTINELLI, P., & PONIACHIK, J. (2004) · Clinical Science · doi:10.1042/cs20030326 · Cited by 700
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569
Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis
Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., & Aoyama, T. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31815591aa · Cited by 248
Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
Lalia, A. Z., Johnson, M. L., Jensen, M. D., Hames, K. C., Port, J. D., & Lanza, I. R. (2015) · Diabetes Care · doi:10.2337/dc14-3101 · Cited by 73
Razny, U., Kiec-Wilk, B., Polus, A., Goralska, J., Malczewska-Malec, M., Wnek, D., Zdzienicka, A., Gruca, A., Childs, C. E., Kapusta, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.05.001 · Cited by 27
Cited by
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Araújo, A. R., Rosso, N., Bedogni, G., Tiribelli, C., & Bellentani, S. (2018) · Liver International · doi:10.1111/liv.13643 · Cited by 401
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Yang, J., Fernández-Galilea, M., Martínez-Fernández, L., González-Muniesa, P., Pérez-Chávez, A., Martínez, J. A., & Moreno-Aliaga, M. J. (2019) · Nutrients · doi:10.3390/nu11040872 · Cited by 292
Therapeutic potential of ectopic olfactory and taste receptors
Lee, S.-J., Depoortere, I., & Hatt, H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0002-3 · Cited by 279
Metadata
- Authors
- He, X.-X., Wu, X.-L., Chen, R.-P., Chen, C., Liu, X.-G., Wu, B.-J., & Huang, Z.-M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-10-06
- Volume
- 11
- Issue
- 10
- Pages
- e0162368
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2528632550
- Cited by
- 129
- References
- 12
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.